20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Down 36.0% in June

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 186,863 shares, a decrease of 36.0% from the June 15th total of 291,990 shares. Based on an average daily volume of 424,508 shares, the short-interest ratio is presently 0.4 days. Approximately 1.5% of the company’s shares are sold short.

Analyst Ratings Changes

Several research firms have issued reports on AIDX. Weiss Ratings began coverage on 20/20 Biolabs in a report on Thursday, May 14th. They set a “sell (e-)” rating on the stock. Maxim Group began coverage on shares of 20/20 Biolabs in a research report on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.00.

20/20 Biolabs Stock Down 2.3%

NASDAQ:AIDX opened at $0.52 on Friday. The company’s fifty day simple moving average is $0.83. The firm has a market capitalization of $6.34 million and a price-to-earnings ratio of -1.85. 20/20 Biolabs has a 1-year low of $0.51 and a 1-year high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.28) EPS for the quarter. The business had revenue of $0.35 million during the quarter.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.